Quote Request
Squamous Cell Carcinoma
With extensive expertise in cancer biology, Alfa Cytology aims to advance the understanding of pancreatic squamous cell carcinoma and the development of targeted therapies through innovative and comprehensive research approaches.
Introduction to Pancreatic Squamous Cell Carcinoma
Pancreatic squamous cell carcinoma is a malignant tumor arising from squamous epithelial cells, which are found in various tissues throughout the body, including the skin, lungs, esophagus, and cervix. pancreatic squamous cell carcinoma is characterized by the abnormal and uncontrolled proliferation of these cells, leading to tumor formation. It is the second most common form of skin cancer, following basal cell carcinoma, but can also occur in other organs. Recently, advancements in genomic and molecular profiling have enhanced the understanding of pancreatic squamous cell carcinoma pathogenesis, paving the way for targeted therapeutic interventions.
Fig. 1 The role of cutaneous squamous cell carcinoma cell-derived EVs on CAF activation in the tumor stroma. (Li C, et al, 2023)
Therapeutics for Pancreatic Squamous Cell Carcinoma
The clinical pipeline for pancreatic squamous cell carcinoma includes a variety of novel agents designed to enhance therapeutic efficacy and minimize side effects. The following are key examples of drugs currently under investigation, each with unique mechanisms of action and targets.
| Therapeutics | Molecular Type | Target | Phase |
|---|---|---|---|
| Erbitux | Monoclonal Antibody | EGFR | Approved for head and neck pancreatic squamous cell carcinoma, ongoing studies in other pancreatic squamous cell carcinoma types to explore additional indications. |
| Ibrance | Small Molecule Inhibitor | CDK4/6 | Phase II clinical trials for pancreatic squamous cell carcinoma, with a focus on combination therapy with other agents. |
| TSR-042 | Monoclonal Antibody | PD-1 | Phase II clinical trials for various solid tumors, including pancreatic squamous cell carcinoma. |
| Cyramza | Monoclonal Antibody | VEGF receptor-2 | Phase II clinical trials for pancreatic squamous cell carcinoma, particularly in combination with chemotherapy. |
| Gilotrif | Small Molecule Inhibitor | EGFR, HER2, and HER4 | Phase II clinical trials for pancreatic squamous cell carcinoma, especially for patients with EGFR mutations. |
Our Services
With state-of-the-art preclinical research facilities and a team of dedicated biologists and scientists, Alfa Cytology provides cancer mechanism research services, modeling services, drug discovery services, diagnostic development services, and preclinical research services for basic research and innovative therapy development for pancreatic squamous cell carcinoma. We are committed to unraveling the complex mechanisms of pancreatic squamous cell carcinoma and providing a full range of services to scientists exploring innovative therapies around the world.
Basic Research Services for Pancreatic Squamous Cell Carcinoma
- Cell Biology Research Services: Conducts comprehensive studies on cellular behaviors, interactions, and responses to various stimuli in pancreatic squamous cell carcinoma.
- Molecular Biology Services: Provides detailed analyses of genetic and molecular mechanisms underlying pancreatic squamous cell carcinoma, including gene expression and mutation profiling.
- Pancreatic Squamous Cell Carcinoma Progression and Metabolic Analysis: Investigates the metabolic pathways and progression mechanisms of pancreatic squamous cell carcinoma to identify potential therapeutic targets and biomarkers.
Pancreatic Squamous Cell Carcinoma Modeling Services
We provide a comprehensive suite of pancreatic squamous cell carcinoma modeling services to support preclinical research. These services are designed to replicate the complexity of pancreatic squamous cell carcinoma in various contexts, enabling detailed studies of tumor biology and therapeutic response. The types of pancreatic squamous cell carcinoma modeling services offered include but are not limited to the following:
Utilizing a diverse array of pancreatic squamous cell carcinoma cell lines, we offer high-throughput screening and mechanistic studies. These models are pivotal for understanding cellular responses to different treatments and for identifying potential drug targets.
Three-Dimensional (3D) Culture Models
Advanced 3D culture systems mimic the tumor microenvironment more accurately than traditional 2D cultures. These models provide insights into cell-cell interactions, drug penetration, and resistance mechanisms.
Patient-Derived Xenograft (PDX) Models
By implanting patient pancreatic squamous cell carcinoma tissue into immunocompromised mice, the PDX model maintains the heterogeneity of the original tumor, which can help evaluate the efficacy of novel therapies.
Genetically Engineered Mouse Models (GEMMs)
GEMMs are designed to carry specific genetic mutations found in human pancreatic squamous cell carcinoma, allowing for the study of tumor development and progression in a controlled genetic background.
Pancreatic Squamous Cell Carcinoma Diagnostic Development Services
- Blood-based Biomarker Discovery
- Tissue Biomarker Discovery
Imaging Services
- Tumor Area Quantification
- Tissue Imaging and Analysis for Immuno-oncology
- Imaging Services for Tumor Microenvironment
- Genomics
- Transcriptomics
- Proteomics
- Epigenomics
- Immune-omics
- Single-Cell Omics
- Spatial Omics
Case Study - A Pan02 Syngeneic Pancreatic Cancer Model
- Model Introduction
The Pan02 syngeneic pancreatic cancer model established with the Pan02 cell line provides a robust preclinical platform for investigating combination immunotherapy strategies against highly resistant pancreatic cancers, including pancreatic squamous cell carcinoma. These models recapitulate key pathological features, including high expression of C-FOXP3, upregulated PD-L1, and an immunosuppressive tumor microenvironment.
- Model Information
- Model: Pan02 Syngeneic Pancreatic Cancer Model
- Animal: C57BL/6 Mice
- Weight: 18-22 g
- Molecular Profile: High C-FOXP3 expression, leading to upregulated PD-L1 and CCL5.
- Cancer Type: Pancreatic Squamous Cell Carcinoma
- Age: 6-8 Weeks
- Cell Line: Murine Pan02 pancreatic cancer cells, engineered to overexpress C-FOXP3 (Pan02-pLV-FOXP3).
- Model Construction
1×106 Pan02-pLV-FOXP3 cells were mixed with matrigel and injected into the right flank of C57BL/6 mice to establish a homologous pancreatic cancer mouse model. Tumor growth was monitored, and when volumes reached approximately 70 mm3, mice were enrolled in subsequent therapeutic experiments.
Fig. 2 Workflow of Pan02 syngeneic pancreatic cancer mice model establishment. (Source: Alfa Cytology)
- In Vivo Efficacy Evaluation
This study employed the established pancreatic cancer model with high C-FOXP3 expression to systematically evaluate the therapeutic effects of PD-L1 monotherapy and PD-L1/CCL5 combination therapy on tumor progression.
- PD-L1 Monotherapy: Compared to the isotype control group, anti-PD-L1 monotherapy achieved an approximate 40-50% inhibition of tumor growth (based on volume comparison from the baseline of 70 mm3 to the end of treatment) in the C57BL/6 mouse model. However, monotherapy failed to achieve complete tumor regression, and a trend of tumor recurrence was observed after treatment cessation.
- PD-L1/CCL5 Combination Therapy: Compared to monotherapy, the combination of PD-L1 and CCL5 antibodies increased tumor inhibition to approximately 80-85%, significantly delaying tumor progression over a 21-day treatment period. Furthermore, the median survival of mice in the combination therapy group was extended from 32 days in the control group to 56 days (p < 0.01), demonstrating significant survival benefits.
Fig. 3 Anti-PD-L1 antibodies enhanced the antitumor effect of CCL5 blockade against pancreatic cancer in the Pan02 syngeneic pancreatic cancer mouse model (n = 6). *p < 0.05, **p< 0.01. Data are presented as mean ± standard error (SEM). (Source: Alfa Cytology)
Alfa Cytology is committed to providing comprehensive solutions for preclinical research and the development of innovative therapies for pancreatic cancer. We provide basic cellular research, genetic/molecular research, diagnostics development, and tumor modeling for different types of pancreatic cancer to meet the full range of customer needs. The types of molecules we can develop involve small-molecule drugs, therapeutic antibodies, peptide drugs, gene therapies, cellular therapies, and more. Our customer service representatives are available 24 hours a day, Monday through Sunday. If interested in our services, please do not hesitate to contact us.
Reference
- Li C, et al. Cutaneous pancreatic squamous cell carcinoma-derived extracellular vesicles exert an oncogenic role by activating cancer-associated fibroblasts. Cell death discovery. 2023, 9(1): 260.
